Dyadic expands C1 platform licensing deal with Rubic One Health for Africa vaccines and biologics

DYADIC INTERNATIONAL INC

Expanded license covers vaccines and therapeutic proteins beyond COVID-19 for human and animal health.
Rubic to pay licensing fee on commercial sales; Dyadic receives equity in Rubic in 2028.
Milestones allow conversion to exclusive license for bulk manufacturing in SADC region.
DYAI-100 (COVID-19 vaccine candidate) is in Phase 1 first-in-human trial, enabling the expansion.
Agreement aims to develop affordable biologics for underserved African countries.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

DYADIC INTERNATIONAL INC entered into Expanded Licensing Agreement with Rubic One Health (effective 2023-04-06).

Action: entry
Agreement: license
Counterparty: Rubic One Health
Effective: 2023-04-06

Exact text from the filing

On April 6, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc., (hereinafter collectively referred to as “Dyadic” or the “Company”) signed an expanded licensing agreement (“the Agreement”) for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to research, develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.

View on SEC.gov

Browse all material agreements →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-23-010055

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.